AR113877A2 - Preparación de relajante de músculo esquelético en formas de dosificación de liberación controlada - Google Patents

Preparación de relajante de músculo esquelético en formas de dosificación de liberación controlada

Info

Publication number
AR113877A2
AR113877A2 ARP180103296A ARP180103296A AR113877A2 AR 113877 A2 AR113877 A2 AR 113877A2 AR P180103296 A ARP180103296 A AR P180103296A AR P180103296 A ARP180103296 A AR P180103296A AR 113877 A2 AR113877 A2 AR 113877A2
Authority
AR
Argentina
Prior art keywords
preparation
dosage forms
controlled release
skeletal muscle
release dosage
Prior art date
Application number
ARP180103296A
Other languages
English (en)
Inventor
Timothy Grinstead
James M Cleveger
Gopi Venkatesh
Original Assignee
Adare Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41434443&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR113877(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adare Pharmaceuticals Inc filed Critical Adare Pharmaceuticals Inc
Publication of AR113877A2 publication Critical patent/AR113877A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente está dirigida a un método para preparar una composición farmacéutica de liberación prolongada que comprende ciclobenzaprina, que comprende recubrir partículas inertes con una composición farmacológica que contiene ciclobenzaprina, a fin de formar perlas de IR, y luego recubrir las perlas IR con una cubierta de liberación prolongada para formar perlas ER.
ARP180103296A 2008-06-20 2018-11-12 Preparación de relajante de músculo esquelético en formas de dosificación de liberación controlada AR113877A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7446408P 2008-06-20 2008-06-20

Publications (1)

Publication Number Publication Date
AR113877A2 true AR113877A2 (es) 2020-06-24

Family

ID=41434443

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP090102268A AR072267A1 (es) 2008-06-20 2009-06-19 Preparacion de relajante de musculo esqueletico en formas de dosificacion de liberacion controlada
ARP180103296A AR113877A2 (es) 2008-06-20 2018-11-12 Preparación de relajante de músculo esquelético en formas de dosificación de liberación controlada

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP090102268A AR072267A1 (es) 2008-06-20 2009-06-19 Preparacion de relajante de musculo esqueletico en formas de dosificacion de liberacion controlada

Country Status (28)

Country Link
US (3) US20090148532A1 (es)
EP (1) EP2303020B1 (es)
JP (1) JP5636364B2 (es)
KR (1) KR101451823B1 (es)
CN (2) CN102065691A (es)
AR (2) AR072267A1 (es)
AU (1) AU2009259993B2 (es)
BR (1) BRPI0914225B1 (es)
CA (1) CA2727935C (es)
CL (1) CL2009001447A1 (es)
CO (1) CO6300903A2 (es)
CR (1) CR11864A (es)
CY (1) CY1118878T1 (es)
DK (1) DK2303020T3 (es)
ES (1) ES2625485T3 (es)
HU (1) HUE032182T2 (es)
IL (1) IL209997A0 (es)
MX (1) MX2010013760A (es)
MY (2) MY173408A (es)
NZ (1) NZ589856A (es)
PL (1) PL2303020T3 (es)
PT (1) PT2303020T (es)
RU (1) RU2540494C2 (es)
SG (1) SG193816A1 (es)
TW (2) TW201503915A (es)
UY (1) UY31928A (es)
WO (1) WO2009155426A1 (es)
ZA (2) ZA201009083B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090148532A1 (en) * 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
WO2010133961A1 (en) * 2009-05-22 2010-11-25 Inventia Healthcare Private Limited Extended release compositions of cyclobenzaprine
EP2501234B1 (en) * 2009-11-20 2017-09-13 Tonix Pharma Holdings Limited Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
US20150086626A1 (en) * 2012-04-17 2015-03-26 Mylan, Inc Stable dosage forms of skeletal muscle relaxants with extended release coating
PT2861223T (pt) * 2012-06-15 2022-11-07 Tonix Pharmaceuticals Inc Composições e métodos de absorção transmucosa
EP2968992B8 (en) 2013-03-15 2020-01-15 Tonix Pharma Holdings Limited Eutectic formulations of cyclobenzaprine hydrochloride and mannitol
CN107072968B (zh) 2014-09-18 2021-01-12 通尼克斯制药控股有限公司 环苯扎林盐酸盐的低共熔混合物配制剂
EP3592337B1 (en) * 2017-03-08 2023-07-05 Cinrx Pharma, LLC Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
EP3723860A1 (en) 2017-12-11 2020-10-21 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
CN109381446A (zh) * 2018-11-26 2019-02-26 正大制药（青岛）有限公司 一种盐酸环苯扎林缓释胶囊
CN111374942B (zh) * 2018-12-30 2022-09-13 鲁南制药集团股份有限公司 一种甾体类肌松药注射液及其制备方法
CN114432266B (zh) * 2021-12-23 2023-03-10 南通联亚药业股份有限公司 一种稳定的盐酸环苯扎林缓释胶囊

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3882246A (en) * 1971-05-21 1975-05-06 Merck & Co Inc Treatment of skeletal muscle disorders with cyclobenzaprine
US4337582A (en) * 1980-09-30 1982-07-06 Airco, Inc. Methods for controlling vapor concentrations in an atmosphere
US4685918A (en) 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
US5047258A (en) 1989-07-14 1991-09-10 Sterling Drug Inc. Aqueous spray-coating process
CN100391438C (zh) * 1999-09-14 2008-06-04 史密丝克莱恩比彻姆公司 制备水性包被小球粒的方法
US6576702B2 (en) 2000-07-20 2003-06-10 Noveon Ip Holdings Corp. Plasticized waterborne polyurethane dispersions and manufacturing process
CA2481236A1 (en) 2002-03-29 2003-10-09 Alza Corporation Volume efficient controlled release dosage form
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
GB0229258D0 (en) * 2002-12-16 2003-01-22 Boots Healthcare Int Ltd Medicinal compositions
WO2005041935A1 (en) 2003-10-21 2005-05-12 Alpharma, Inc. Pharmaceutical formulations containing quetiapine
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
US20060263429A1 (en) * 2005-05-20 2006-11-23 Hengsheng Feng Compressible mixture, compressed pharmaceutical compositions, and method of preparation thereof
AU2007230546A1 (en) * 2006-03-24 2007-10-04 Panacea Biotec Ltd. Antibiotic compositions of modified release and process of production thereof
US20090148532A1 (en) 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms

Also Published As

Publication number Publication date
JP2011525188A (ja) 2011-09-15
AU2009259993B2 (en) 2013-10-31
CY1118878T1 (el) 2018-01-10
US8137734B2 (en) 2012-03-20
CO6300903A2 (es) 2011-07-21
IL209997A0 (en) 2011-02-28
CL2009001447A1 (es) 2009-08-21
EP2303020A4 (en) 2013-12-04
EP2303020B1 (en) 2017-02-22
US20090148532A1 (en) 2009-06-11
MY173408A (en) 2020-01-22
BRPI0914225A2 (pt) 2017-11-07
NZ589856A (en) 2012-06-29
AU2009259993A1 (en) 2009-12-23
CN102065691A (zh) 2011-05-18
RU2540494C2 (ru) 2015-02-10
US20100098832A1 (en) 2010-04-22
PL2303020T3 (pl) 2017-08-31
EP2303020A1 (en) 2011-04-06
TW201004615A (en) 2010-02-01
JP5636364B2 (ja) 2014-12-03
AR072267A1 (es) 2010-08-18
BRPI0914225A8 (pt) 2018-02-06
CA2727935A1 (en) 2009-12-23
KR101451823B1 (ko) 2014-10-16
UY31928A (es) 2010-01-29
TWI458480B (zh) 2014-11-01
MX2010013760A (es) 2011-03-29
ZA201009083B (en) 2012-03-28
ES2625485T3 (es) 2017-07-19
CN106860430A (zh) 2017-06-20
WO2009155426A1 (en) 2009-12-23
RU2011101918A (ru) 2012-07-27
MY153712A (en) 2015-03-13
BRPI0914225B1 (pt) 2021-08-31
SG193816A1 (en) 2013-10-30
US20120196028A1 (en) 2012-08-02
ZA201109534B (en) 2013-10-30
HUE032182T2 (en) 2017-09-28
CR11864A (es) 2011-05-16
DK2303020T3 (en) 2017-05-01
PT2303020T (pt) 2017-06-02
KR20110025654A (ko) 2011-03-10
TW201503915A (zh) 2015-02-01
CA2727935C (en) 2017-05-30

Similar Documents

Publication Publication Date Title
AR113877A2 (es) Preparación de relajante de músculo esquelético en formas de dosificación de liberación controlada
CR11740A (es) Composiciones que comprenden fármacos levemente básicos y formas de dosificación de liberación controlada
UY32427A (es) Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
ECSP11011278A (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
AR052238A1 (es) Formulacion de tabletas estables
ECSP10010295A (es) Formulacion de anticuerpo
BR112013019223A2 (pt) forma de dosagem para liberação modificada, processo para a fabricação de um comprimido e processo para a fabricação de uma forma de dosagem oral
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
CL2014002283A1 (es) Forma de dosificacion oral solida de liberacion inmediata que comprende particulas que comprenden un nucleo con un primer agente activo, un recubrimiento con un segundo agente activo sobre el y un material sensible al ph acido sobre dicho nucleo recubierto; proceso para prepararla; metodo de tratamiento; y uso para tratar dolor.
EA201491675A1 (ru) Новые вещества
CL2007002121A1 (es) Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab
CR20130033A (es) Formulaciones de rifaximina y usos de las mismas
ECSP088889A (es) Forma nueva de administración de racecadotril
CL2012002909A1 (es) Procedimiento de preparación de una composición farmacéutica que comprenden a) un centro granulado constituido por granos de principio activo aglomerados en presencia de aglomerante y b) una capa de recubrimiento de dicho centro granulado constituido por matriz grasa; composición farmacéutica; y su uso para administración oral
CL2013002504A1 (es) Preparacion farmaceutica solida recubierta que comprende a lo menos un ingrediente activo y porque el recubrimiento tiene un espesor de 0,1 a 100nm, de preferencia de 0,3 a 50 nm y mas preferentemente de 0,5 a 35 nm; y su metodo de preparacion
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
UY35693A (es) Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso
DOP2012000279A (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona
CL2016001100A1 (es) Formulación compuesta que comprende gránulos húmedos de tadalafilo y lactosa y/o manitol y una mezcla de amlodipina en una cantidad de 6-16 partes de tadalafilo y amlodipina por 100 partes de la composición; método para prepararla; uso para tratar una enfermedad cardiovascular, disfunción eréctil o una combinación de ellas.
BR112016017776A8 (pt) forma cristalina ou forma sólida de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidróxi-4-metil-ciclo-hexilamino)-pirimidina-5-carboxamida, método de preparo, método de purificação, composto, composição farmacêutica e uso de forma cristalina ou forma sólida
CL2007002975A1 (es) Composicion farmaceutica de liberacion modificada que comprende microesferas recubiertas con un farmaco musculo relajante y un farmaco aine; proceso de preparacion y uso en el tratamiento de espasticidad, desordenes relacionados con padecimientos musculares y/o musculo esqueleticos.
CL2008001563A1 (es) Compuestos derivados de benzodioxanos condensados con heterociclos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, crisis de panico, entre otras.
BR112013022930A2 (pt) composição farmacêutica, uso de uma composição farmacêutica, e, processo para produzir uma composição farmacêutica
UY31903A (es) 7-sulfanilmetil-,7-silfinilmetil-y7-sulfonilmetilindoles sustituidos y el uso de los mismos

Legal Events

Date Code Title Description
FC Refusal